Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May 9;114(5):641-642.
doi: 10.1093/jnci/djac020.

Bias and Pancreatic Cancer Reporting

Howard S Hochster  1 , H Richard Alexander  1
Affiliations
Editorial

Bias and Pancreatic Cancer Reporting

Howard S Hochster et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Janssen QP, van Dam JL, Doppenberg D, et al. FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium. J Natl Cancer Inst. 2022;114(5):695–703. - PMC - PubMed
    1. Gooiker GA, Lemmens VEPP, Besselink MG, et al. Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg. 2014;101(8):1000–1005. - PubMed
    1. Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782–794. - PMC - PubMed
    1. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–969. - PMC - PubMed
    1. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–17. - PMC - PubMed